source
- Takeda’s oral psoriasis drug outperforms Bristol Myers’ Sotyktu in Phase 3 trialTakeda announced that its experimental oral medication for plaque psoriasis achieved superior results compared with Bristol Myers Squibb’s Sotyktu in a head-to-head Phase 3 study. The trial measur…
- Long Covid research faces funding cut as NIH terminates grant, highlighting political neglectSteven Phillips, a science strategist at the COVID Collaborative, notes that a two‑year study of long Covid’s impact on the nervous system was halted when the NIH withdrew its RECOVER grant, labeli…